Drugs / FIPAXALPARANT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05626751 | Nov 2022 → Feb 2025 | diffuse cutaneous systemic sclerosis | Amgen | Terminated | No outcome recorded |
| Phase 2 | NCT05032066 | Jan 2022 → Jul 2024 | idiopathic pulmonary fibrosis | Amgen | Terminated | Missed primary |
| Phase 2 | NCT04781543 | Nov 2021 → Feb 2025 | diffuse cutaneous systemic sclerosis | Amgen | Terminated | Missed primary |
| Phase 2 | NCT01651143 | Jan → Nov 2013 | systemic sclerosis | Sanofi | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIPAXALPARANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3621969 ↗ |
| Known as | A-003423457 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3621969 ↗ |
| Known as | CZN-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3621969 ↗ |
| Known as | HZN-825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04781543 ↗ |
| Known as | SAR100842 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651143 ↗ |
| Action | Inhibit | “a potent selective oral antagonist of the LPA1 receptor” PMID 29732731 ↗ Nov 2017 |
| Modality | Small molecule | — CHEMBL3621969 ↗ |
| Route | Oral | “Route of administration: oral” NCT01651143 ↗ |
| Target | LPAR1 | “a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1)” NCT05032066 ↗ |